Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: A systematic review and meta-analysis

Clinical Immunology

Volumn 170, Issue , 2016, Pages 61-69

  Qiao, Yong chao ^a,b   Shen, Jian ^a   Hong, Xue zhi ^a   Liang, Ling ^a   Bo, Chao sheng ^a   Sui, Yi ^a   Zhao, Hai lu ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Interleukin 10; Meta analysis; Regulatory T cells; Transforming growth factor ; Type 1 diabetes mellitus

Indexed keywords

INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

CD4+ CD25+ T LYMPHOCYTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; MALE; METABOLISM;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84981194186     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.08.004     Document Type: Review

References (57)

1. [1] Elaziz, D.S., Hafez, M.H., Galal, N.M., Meshaal, S.S., El Marsafy, A.M., CD4(+) CD25(+) cells in type 1 diabetic patients with other autoimmune manifestations. J. Adv. Res. 5 (2014), 647–655.
2. [2] Brusko, T., Atkinson, M., Treg in type 1 diabetes. Cell Biochem. Biophys. 48 (2007), 165–175.
3. [3] Jin, Y., Chen, X., Podolsky, R., Hopkins, D., Makala, L.H., Muir, A., et al. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin. Immunol. 130 (2009), 272–279.
4. [4] Milicevic, Z., Knezevic, J., Sabioncello, A., Roglic, G., Rocic, B., Beta-cell secretory function and CD25 + lymphocyte subsets in the early stage of type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 112 (2004), 181–186.
5. [5] Yin, Y.W., Sun, Q.Q., Zhang, B.B., Hu, A.M., Wang, Q., Liu, H.L., et al. The lack of association between interleukin-6 gene − 174 G/C polymorphism and the risk of type 1 diabetes mellitus: a meta-analysis of 18,152 subjects. Gene 515 (2013), 461–465.
6. [6] Tan, T., Xiang, Y., Chang, C., Zhou, Z., Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review. Clin. Rev. Allergy Immunol. 47 (2014), 234–243.
7. [7] Askenasy, E.M., Askenasy, N., Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity?. Autoimmun. Rev. 12 (2013), 633–637.
8. [8] Brusko, T., Bluestone, J., Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur. J. Immunol. 38 (2008), 931–934.
9. [9] Frisk, G., Hansson, T., Dahlbom, I., Tuvemo, T., A unifying hypothesis on the development of type 1 diabetes and celiac disease: gluten consumption may be a shared causative factor. Med. Hypotheses 70 (2008), 1207–1209.
10. [10] Van den Driessche, A., Eenkhoorn, V., Van Gaal, L., De Block, C., Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth. J. Med. 67 (2009), 376–387.
11. [11] Jaeckel, E., Mpofu, N., Saal, N., Manns, M.P., Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm. Metab. Res. 40 (2008), 126–136.
12. + T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann. N. Y. Acad. Sci. 1079 (2006), 9–18.
13. − T cells. J. Clin. Invest. 112 (2003), 1437–1443.
14. + T cells. Cell. Mol. Immunol. 3 (2006), 189–195.
15. + regulatory T cells: current controversies and future perspectives. Eur. J. Immunol. 36 (2006), 2832–2836.
16. + regulatory T cells. Int. Immunol. 16 (2004), 1643–1656.
17. [17] Cabrera, S.M., Rigby, M.R., Mirmira, R.G., Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr. Mol. Med. 12 (2012), 1261–1272.
18. [18] Korholz, D., Banning, U., Bonig, H., Grewe, M., Schneider, M., Mauz-Korholz, C., et al. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. Blood 90 (1997), 4513–4521.
19. [19] Letterio, J.J., Roberts, A.B., Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16 (1998), 137–161.
20. [20] King, C., Davies, J., Mueller, R., Lee, M.S., Krahl, T., Yeung, B., et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 8 (1998), 601–613.
21. [21] Azar, S.T., Salti, I., Zantout, M.S., Major, S., Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients. J. Clin. Endocrinol. Metab. 85 (2000), 4680–4682.
22. [22] Kretowski, A., Maciej, K., Ida, K., The analysis of in vitro transforming growth factor-beta1 (TGF-beta1) production by peripheral blood in overt and pre-clinical type 1 diabetes mellitus. Immunol. Lett. 71 (2000), 85–89.
23. [23] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62 (2009), 1006–1012.
24. [24] Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (cited 2011 Oct 20).
25. [25] Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin-Su, K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109 (2002), 131–140.
26. high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin. Exp. Immunol. 173 (2013), 207–216.
27. + T cell subsets in LADA patients. Chin. J. Diabetes 13 (2006), 428–431 (in Chinese).
28. + T cell subset in autoimmune diabetes patients. Mod. Hosp. 7 (2007), 18–19 (in Chinese).
29. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154 (2008), 353–359.
30. [30] Lindley, S., Dayan, C.M., Bishop, A., Roep, B.O., Peakman, M., Tree, T.I., Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005), 92–99.
31. + T cell subsets in patients with latent autoimmune diabetes in adults. Chinese J. Immunol. 22 (2006), 771–774 (in Chinese).
32. [32] Zhang, S., The Clinical and Laboratory Study of Differential Diagnosis of Young and Middle-Aged Non-Obses Diabetes Patients. 2009, Peking Union Medical College Hospital (in Chinese).
33. + regulatory cells in peripheral blood of T1DM patients and its influence with insulin therapy. Shandong Med. J. 54 (2014), 78–79 (in Chinese).
34. − regulatory T cell in the peripheral blood of patients with type 1 diabetes mellitus. Chin. J. Diabetes 17 (2009), 473–476 (in Chinese).
35. [35] Tao, Z., Shirong, Z., Jing, Z., Relationships of latent autoimmune diabetes in adults with regulatory T cells and Foxp3 expression. J. Immunol. 27 (2011), 1063–1067 (in Chinese).
36. + regulatory T cells in patients with diabetes. Acta Univ. Med. Nanjing 32 (2012), 509–514 (in Chinese).
37. + T cell subset from children with type 1 diabetes. Chin. J. Microbiol. Immunol. 30 (2010), 309–317 (in Chinese).
38. [38] Alonso, N., Martinez-Arconada, M.J., Granada, M.L., Soldevila, B., Canton, A., Mate, J.L., et al. Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis. Endocrine 35 (2009), 420–428.
39. + regulatory cells and cytokines in peripheral blood of T1DM children. Chin. J. Cell. Mol. Immunol. 29 (2013), 76–79 (in Chinese).
40. [40] Dai, Y.L., Fu, J.F., Liang, L., Dong, G.P., [A 10-year review of childhood type 1 diabetes mellitus and the clinical value of interleukin-10 in diabetic ketoacidosis]. Zhongguo Dang Dai Er Ke Za Zhi 12 (2010), 849–854.
41. [41] You-fei, F., Jing, W., Song, Y., Expressions of IL-10 and TGF-β and their relations with islet beta cell function in adults with latent autoimmune diabetes. J. Shangdong Univ. 47 (2009), 15–19 (in Chinese).
42. [42] He, J.S., Xie, P.S., Luo, D.S., Sun, C.J., Zhang, Y.G., Liu, F.X., Role of immune dysfunction in pathogenesis of type 1 diabetes mellitus in children. Asian Pac. J. Trop. Med. 7 (2014), 823–826.
43. [43] Yan-ling, L., Huan-huan, C., Ye, C., Related cytokines expression level in peripheral blood of patients with diabetes mellitus and autoimmune thyroid disease. Chin. J. Clin. 7 (2013), 11201–11206 (in Chinese).
44. [44] Li, Y.-l., Th1/Th2/Th17/Treg Cytokines Expression Levels in the Periphral Blood of Type 2 Diabetes Patients. 2014, Southern Medical University (in Chinese).
45. [45] Azar, S.T., Major, S.C., Safieh-Garabedian, B., Altered plasma levels of nerve growth factor and transforming growth factor-beta2 in type-1 diabetes mellitus. Brain Behav. Immun. 13 (1999), 361–366.
46. [46] Zorena, K., Malinowska, E., Raczynska, D., Mysliwiec, M., Raczynska, K., Serum concentrations of transforming growth factor-beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J. Diabetes Res., 2013, 2013, 614908.
47. [47] Chentoufi, A.A., Binder, N.R., Berka, N., Abunadi, T., Polychronakos, C., Advances in type I diabetes associated tolerance mechanisms. Scand. J. Immunol. 68 (2008), 1–11.
48. [48] Ryden, A., Faresjo, M., Altered immune profile from pre-diabetes to manifestation of type 1 diabetes. Diabetes Res. Clin. Pract. 100 (2013), 74–84.
49. + T-cell fraction. PLoS One, 2, 2007, e146.
50. [50] Arif, S., Tree, T.I., Astill, T.P., Tremble, J.M., Bishop, A.J., Dayan, C.M., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 (2004), 451–463.
51. [51] Marek-Trzonkowska, N., Mysliwiec, M., Dobyszuk, A., Grabowska, M., Derkowska, I., Juscinska, J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets — results of one year follow-up. Clin. Immunol. 153 (2014), 23–30.
52. [52] Bluestone, J.A., Buckner, J.H., Fitch, M., Gitelman, S.E., Gupta, S., Hellerstein, M.K., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med., 7, 2015, 315ra189.
53. + T-cells in type 1 diabetes. Diabetes 54 (2005), 1407–1414.
54. [54] Zahran, A.M., Elsayh, K.I., Metwalley, K.A., Regulatory T cells in children with recently diagnosed type 1 diabetes. Indian J. Endocrinol. Metab. 16 (2012), 952–957.
55. [55] Yang, T.T., Song, S.J., Xue, H.B., Shi, D.F., Liu, C.M., Liu, H., Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 2010–2015.
56. [56] Mysliwska, J., Zorena, K., Semetkowska-Jurkiewicz, E., Rachon, D., Suchanek, H., Mysliwski, A., High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur. Cytokine Netw. 16 (2005), 117–122.
57. [57] Gabbay, M.A., Sato, M.N., Duarte, A.J., Dib, S.A., Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin. Exp. Immunol. 168 (2012), 60–67.